Expanding Pharmacogenomics for More Personalized Healthcare

March 19, 2025 – St. Petersburg, FL – In a significant move for the future of precision medicine, InformedDNA, a leader in applied genomics, has announced its acquisition of Coriell Life Sciences (CLS), a pioneer in pharmacogenomics and clinical decision support. This strategic acquisition enhances InformedDNA’s ability to provide comprehensive, personalized healthcare solutions by integrating Coriell’s pharmacogenomic capabilities into its genetic counseling and test interpretation services.

A Transformational Merger for Precision Medicine

Coriell Life Sciences, based in Philadelphia, specializes in pharmacogenomics (PGx)—the study of how genetics influence a person’s response to medication. By tailoring treatments to an individual’s genetic profile, PGx helps reduce adverse drug reactions, improve medication efficacy, and lower healthcare costs. The acquisition significantly broadens InformedDNA’s offerings, ensuring that patients, healthcare providers, and payers can access more data-driven, personalized treatment decisions.

“Pharmacogenomics is a critical component of precision healthcare,” said Dr. Surya Singh, CEO of InformedDNA. “Coriell Life Sciences brings unparalleled expertise in genetic testing and complex molecular analysis, strengthening our ability to provide patients with tailored, effective treatments.”

Bringing Genomic Insights to Everyday Healthcare

Coriell Life Sciences’ flagship pharmacogenomic program, Corigen®, supports large-scale medication risk management, helping health plans, employers, and health systems identify the safest and most effective medications for their patients. Additionally, Coriell provides expert pharmacogenomic research analysis for laboratories, further reinforcing its commitment to advancing genomic science in clinical settings.

With this acquisition, InformedDNA is integrating Coriell’s capabilities into its DNAimpact® precision health platform. This combined solution enables healthcare providers to:

• Match medications to an individual’s genetic makeup, reducing adverse drug reactions and increasing efficacy.
• Leverage real-time genetic insights to guide treatment decisions for chronic conditions, oncology, and polypharmacy.
• Support patients with interactive education and expert counseling, ensuring they make informed healthcare choices based on their unique genetic profile.

Leadership and Future Growth

As part of the acquisition, Scott Megill, CEO and co-founder of Coriell Life Sciences, will assume the role of Chief Commercial Officer at InformedDNA. With a strong background in pharmacogenomics and clinical decision support, Megill sees the merger as a significant advancement for precision medicine.

“By combining our strengths in genetic counseling and pharmacogenomics, we are setting a new standard for personalized healthcare,” said Megill. “Through the expanded DNAimpact platform, we are giving patients and healthcare teams the tools they need to make more informed, data-driven decisions that improve outcomes and reduce costs.”

The Future of Precision Health

The acquisition underscores InformedDNA’s commitment to scaling access to genetic-based healthcare solutions. As genomics and precision medicine continue to transform healthcare, this merger ensures that more patients can benefit from cutting-edge advances in medication safety, treatment efficacy, and overall health management.

For more information about InformedDNA and Coriell Life Sciences, visit:

• InformedDNA: www.InformedDNA.com
• Coriell Life Sciences: www.Coriell.com